Improvement of Bone Metabolism in Prepubertal Girls with Turner Syndrome Following Long-term Pegylated Growth Hormone Treatment
Hormone and Metabolic Research · 01.02.2025 · 57 (02) · 101-105
DOI: 10.1055/a-2407-9446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.02.2025. Verfasst von Xinying Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health,…. Hauptthemen laut MEDLINE: Turner Syndrome, Human Growth Hormone, Bone and Bones, Polyethylene Glycols. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
The study aims to assess the improvement in bone metabolism in prepubertal girls with Turner Syndrome (TS) after long-term polyethylene glycol recombinant human Growth Hormone (PEG-rhGH) treatment. A 12-month longitudinal prospective study was conducted with 28 prepubertal girls diagnosed with TS. Participants were divided into two groups: 18 received PEG-rhGH therapy (0.1–0.25 mg/kg/week) and 10 did not. Anthropometric measurements, bone turnover markers (BTMs), and serum levels of IGF-1, calcium, and phosphate were collected at baseline and after 12 months. BTMs included bone alkaline phosphatase (BAP), Type I collagen propeptide (CICP), Type I collagen telopeptide (CTX), and fibroblast growth factor 23 (FGF23). After 12 months of PEG-rhGH therapy, the treatment group showed significant increases in growth velocity (GV) and height standard deviation scores (HtSDS). Serum IGF-1 levels increased rapidly within one month and remained elevated. BTMs indicated enhanced bone formation, significantly increasing BAP and CICP, while CTX levels remained low. FGF23 levels initially rose slightly but declined below baseline by 12 months. Elevated blood phosphate levels were observed. PEG-rhGH therapy in children with TS significantly improves linear growth and enhances bone formation markers, benefiting bone metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Department of Pediatrics, Liangxiang Hospital of Beijing Fangshan District, Beijing, China.
- Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zitieren
APA
Gao, X., Cao, B., Chen, J., Liu, M., Peng, Y., & Gong, C. (2025). Improvement of Bone Metabolism in Prepubertal Girls with Turner Syndrome Following Long-term Pegylated Growth Hormone Treatment. Hormone and Metabolic Research, 57(02), 101-105. https://doi.org/10.1055/a-2407-9446
Vancouver
Gao X, Cao B, Chen J, Liu M, Peng Y, Gong C. Improvement of Bone Metabolism in Prepubertal Girls with Turner Syndrome Following Long-term Pegylated Growth Hormone Treatment. Hormone and Metabolic Research. 2025;57(02):101-105. doi:10.1055/a-2407-9446
BibTeX
@article{Gao2025,
author = {Gao, Xinying and Cao, Bingyan and Chen, Jiajia and Liu, Meijuan and Peng, Yaguang and Gong, Chunxiu},
title = {Improvement of Bone Metabolism in Prepubertal Girls with Turner Syndrome Following Long-term Pegylated Growth Hormone Treatment},
journal = {Hormone and Metabolic Research},
year = {2025},
volume = {57},
number = {02},
pages = {101--105},
doi = {10.1055/a-2407-9446}
}
EUVIMED